Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8151828 | 0.86 | MAPT (0.34) | MAPTATMKDM4EALDH1A1 | |
| SCHEMBL6696470 | 0.83 | MAPT (0.38) | MAPTATMKDM4EALDH1A1MEN1 | |
| SCHEMBL6695877 | 0.74 | MAPT (0.39) | MAPTATMKDM4EALDH1A1MEN1 | |
| SCHEMBL6697459 | 0.74 | KMT2A (0.39) | MAPTATMKDM4EALDH1A1MEN1 | |
| SCHEMBL6695417 | 0.73 | KDM4E (0.47) | MAPTATMKDM4EALDH1A1POLB | |
| SCHEMBL6698332 | 0.73 | KMT2A (0.40) | MAPTATMKDM4EALDH1A1MEN1 | |
| SCHEMBL8151831 | 0.73 | MAPT (0.35) | MAPTATMKDM4EALDH1A1MEN1 | |
| SCHEMBL6693184 | 0.73 | MAPK14 (0.35) | MAPTATMALDH1A1MEN1KMT2A | |
| SCHEMBL6697320 | 0.73 | MAPT (0.40) | MAPTATMKDM4EALDH1A1TDP1 | |
| SCHEMBL6694814 | 0.72 | CYP1A2 (0.38) | MAPTATMKDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835726-B2 | Pyrimidine derivatives | AMGEN INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040006068-A1 | Pyrimidine derivatives | TULARIK INC. | 2004-01-08 | — | — | US | disclosed |
| EP-1056742-B1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK INC (US) | 2003-07-23 | — | — | EP | disclosed |
| US-6528513-B2 | Viricides; especially cytomegalo virus | TULARIK INC | 2003-03-04 | — | — | US | disclosed |
| US-20010018436-A1 | Pyrimidine derivatives | TULARIK INC. | 2001-08-30 | — | — | US | disclosed |
| US-6200977-B1 | USEFUL IN TREATING AND SUPPRESSING HUMAN CYTOMEGALOVIRUS | TULARIK INC. | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018436-A1 | Pyrimidine derivatives | TYMP, TYMS, UMPS | MAPT 1762/4885ATM 2349/4885KDM4E 2819/4885 |
| US-20040006068-A1 | Pyrimidine derivatives | TYMP, TYMS, UMPS | MAPT 1762/4885ATM 2349/4885KDM4E 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.